A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure

Last updated: August 20, 2024
Sponsor: Mayo Clinic
Overall Status: Completed

Phase

N/A

Condition

Diabetic Macular Edema

Diabetic Foot Ulcers

Diabetic Kidney Disease

Treatment

LIFELEAF Smartwatch

Clinical Study ID

NCT05904769
22-010799
  • Ages > 18
  • All Genders

Study Summary

The purpose of this research is to compare blood glucose, blood pressure and electrocardiogram (ECG) readings on the LIFELEAF Smartwatch compared to standard methods of measurement.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diabetic patients on insulin undergoing four times daily blood sugar checks as partof standard of care.

  • Patients undergoing continuous monitoring for heart rate and blood pressure as partof their routine care.

  • Patients undergoing catheter ablation for atrial fibrillation.

Exclusion

Exclusion Criteria:

  • Patients unable to provide informed consent.

  • Patients without arms as these are needed to wear the wrist-based sensor.

Study Design

Total Participants: 87
Treatment Group(s): 1
Primary Treatment: LIFELEAF Smartwatch
Phase:
Study Start date:
May 31, 2023
Estimated Completion Date:
July 31, 2024

Connect with a study center

  • Mayo Clinic Minnesota

    Rochester, Minnesota 55905
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.